(OCUP) – Globe Newswire
-
Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
-
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive
-
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
-
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
-
Ocuphire Pharma to Present in the BIO CEO & Investor Conference
-
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Ocuphire Pharma Strengthens Leadership Team with Key Appointments
-
Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference
-
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) L
-
Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII
-
Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer
-
Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update
-
Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy
-
Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director
-
Ocuphire Pharma to Present at AAO 2023 and Eyecelerator Retina Showcase
-
Ocuphire Pharma to Present at Euretina and Retina Society Conferences in October
-
Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agoni
-
Ocuphire Pharma to Participate in Three Upcoming Investment Bank Conferences
-
Ocuphire Pharma to Present at ESCRS 2023 and MODLive! Conferences in September
-
Abstract on ZETA-1 Study of APX3330 Receives Award at Women in Ophthalmology (WIO) Summer Symposium
-
Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update
-
Ocuphire Pharma to Present at the Canaccord 43rd Annual Growth Conference and the H.C. Wainwright Ophthalmology Conference in August
-
Ocuphire to Present at American Society of Retina Specialists Annual Meeting and OIS Retina Innovation Summit
-
Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Ocuphire Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association’s Annual Conference
-
Ocuphire Announces Late Breaking Presentation on APX3330 ZETA-1 Clinical Data at American Diabetes Association Annual Conference
-
Ocuphire Presents APX3330 ZETA-1 Data at Clinical Trials at the Summit (CTS) 2023
-
Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Ocuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate Update
-
Ocuphire Announces APX3330 and Nyxol® Data Presentations at ASCRS 2023 and Eyecelerator
-
Ocuphire Provides Corporate Update and Reiterates Previous Guidance on Clinical Programs
-
Ocuphire Appoints Rick Rodgers as Interim Chief Executive Officer
-
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Year Ended 2022 and Provides Corporate Update
-
Ocuphire Announces APX3330 and Nyxol® Data Presentations at ARVO 2023 Annual Meeting
-
Ocuphire Announces APX3330 Phase 2 Data Presentations at Retina Meetings
-
Ocuphire Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol® Eye Drops for Reversal of Mydriasis
-
Ocuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA
-
Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia
-
Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol® Eye Drops for Reversal of Mydriasis
-
Ocuphire to Present at Five Upcoming Investor/Industry Conferences
-
Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances
-
Ocuphire Pharma Announces Financial Results for Third Quarter 2022 and Provides Corporate Update
-
Ocuphire Announces Peer-Reviewed Publication in BMC Ophthalmology for Nyxol® and Strategic Partnership with American Society of Ophthalmic Administrators (ASOA)
-
Ocuphire Announces Six Poster Presentations on Nyxol and APX3330 at the American Academy of Optometry Annual Meeting
-
Ocuphire Pharma to Present at the MicroCap Rodeo Windy City Roundup 2022 Conference
-
Ocuphire Pharma Hosting Key Opinion Leader Event on Oral APX3330 for Diabetic Eye Disease
-
Ocuphire Expands Medical Advisory Board with Seven New KOLs and Strengthens Leadership Team
Back to OCUP Stock Lookup
